Brain Disorders News
-
Showcase
Neeuro (Singapore) and epihunter (Belgium) partner to create new and innovative digital solutions for people with brain disorders
On March 15th 2015, Tim Buckinx’ son said: “Papa, you work in digital, can’t you create a light that turns on when my brain switches off?” At ten years old, he was simply fed up with the daily impact of his refractory epilepsy. That pain became a vision, and that vision became the Belgian digital therapeutics company epihunter, aimed at enabling people with a brain ...
By Epihunter NV
-
Elucid Appoints Dr. Michael Lesh to Board of Directors
BOSTON, November 3, 2022 – Elucid, Inc., a leading medical technology company providing physicians with AI-powered imaging analysis software to characterize cardiovascular disease, today announced the addition of Michael D. Lesh, MD, FACC, to its Board of Directors. “We look forward to what Dr. Lesh will bring to the board with his extensive background as a cardiologist, medtech ...
By Elucid
-
Neuropathix, Inc. Highlights Revenue Related to its Grant Award with NIH-NINDS
The three-year $2.97 million Phase 2 STTR Study Grant through the NIH HEAL Initiative (Helping End Addiction Long-term) is providing funding specifically in the Development of KLS-13019 for Neuropathic Pain DOYLESTOWN, PA – May 25, 2022 – Neuropathix, Inc. (“Neuropathix” or the “Company”) (OTCQB:NPTX), a socially responsible pain management life sciences ...
-
UT Health San Antonio offers summer program for people with aphasia
The news of actor Bruce Willis’ aphasia diagnosis is drawing attention to a condition that is fairly common but not well understood by the general public. Aphasia is a condition that affects a person’s ability to communicate. People with aphasia can have difficulty understanding or expressing themselves verbally, in writing — or both. “Most people haven’t heard of ...
By BioMedSA
-
Neuropathix, Inc. Highlights Positive Preclinical Study Results on Lead Drug Candidate KLS-13019
Published Preclinical Data Shows KLS-13019 More Effective Than Cannabidiol (CBD) in Prevention, Reversal of Chemotherapy-Induced Peripheral Neuropathy (CIPN) DOYLESTOWN, PA – April 13, 2022 – Neuropathix, Inc. (“Neuropathix” or the “Company”) (OTCQB: NPTX), a socially responsible, pioneering life-sciences company devoted to addressing the opioid crisis, ...
-
Neuropathix, Inc. CEO Issues New Letter to Shareholders; Updates Market on Milestones in Research and Funding
DOYLESTOWN, PA / ACCESSWIRE / April 6, 2022 / Neuropathix, Inc. (“Neuropathix” or the “Company”) (OTCQB:NPTX), a socially responsible pain management life sciences company, announced today that its CEO Dean Petkanas has issued a letter to its shareholders, providing commentary on the Company’s recently achieved milestones, updates on its research and financial ...
-
Inscopix Expands Strategic Partnership with GRINTECH to Become Exclusive Global Supplier of GRIN lenses
Inscopix, Inc., a neuroscience company helping decode the brain for tomorrow’s treatments, announced that it is expanding its strategic supplier partnership with leading gradient index (GRIN) lens manufacturer GRINTECH GmbH to be the sole exclusive seller of GRIN lenses for neuroscience research applications. Inscopix offers innovative miniature-microscope (miniscope) based imaging ...
-
Inscopix Expands Applications with Blood Flow Imaging to Study Relationship between Brain Activity and Vascular Dynamics
Inscopix, Inc., a neuroscience company helping decode the brain for tomorrow’s treatments, announced that it has launched a new application for its miniscope-based platforms to investigate neuronal activity and blood flow simultaneously, a novel research method that may prove critical to studying neurovascular dynamics in the context of aging, dementia, stroke and other debilitating ...
-
New National Survey of People Living with Bipolar I Disorder Provides Insights Into Disease-Related Challenges and the Treatment Journey
Results from a newly released survey provide insights from adults living with bipolar I disorder (BD-I)* in the United States (U.S.) on the burden of living with this serious mental health condition and their experiences with treatment. This research was conducted in support of Alkermes' commitment to understanding the unique needs of people living with BD-I and supporting increased disease ...
By Alkermes
-
Neuropathix, Inc. Chooses Purisys for Process Optimization and Scale Up of Its Lead Drug Candidate KLS-13019
DOYLESTOWN, PA / ACCESSWIRE / November 17, 2021 / Neuropathix, Inc. (“Neuropathix” or the “Company”) (OTCQB:NPTX), a socially responsible life sciences company focused on the research and development of a non-opioid platform of therapeutics to treat chronic and acute inflammation, and neuropathic pain, announced today that it has chosen to engage Purisys LLC to optimize ...
-
Neuropathix, Inc. Forms Dermique Incorporated its New Wholly Owned Subsidiary for the Ownership and Commercialization of the Company’s Over-The-Counter Cosmeceutical Assets
Cosmeceutical Assets Include Company’s Lead Anti-inflammatory OTC Cosmeceutical Compound called LEA™ (Limonenyldihydroxybenzyl Ethoxycarbonyl Azetidine) Company’s Strategy is to Enable Dermique to Focus on Commercializing Near Term Revenue Drivers like LEA™, Other Cosmeceuticals DOYLESTOWN, PA / ACCESSWIRE / August 24, 2021 / Neuropathix, Inc. (“Neuropathix” ...
-
Faster & Better EEG Tests with Zeto Health Technology Podcast with Aswin Gunasekar, CEO & Founder, Zeto
For the August installment of the Healthtech Leader of the Month series, we interviewed Aswin Gunasekar, founder and CEO of Zeto. Zeto is a device-driven platform for acquiring, accessing, and interpreting electroencephalograms (EEGs). An EEG is a test used to evaluate electrical activity in the ...
By Zeto, Inc.
-
Neuropathix, Inc. Announces Publication of PCT Patent Application for the Treatment of Radiation Dermatitis and Other Skin Disorders
Neuropathix, Inc. (“Neuropathix” or the “Company”) (OTCQB:NPTX), a socially responsible pain management life sciences company, announced today the publication of the global Patent Cooperation Treaty (PCT) Patent under Publication No. WO/2021/097351 “Functionalized 1,3-Benzene Diols and Their Method of Use for the Treatment of Radiation Dermatitis and Other Skin ...
-
Wireless EEG for Fast Prep and Easy Use: Q&A with Aswin Gunasekar, CEO of Zeto
Electroencephalography (EEG) devices are incredibly helpful in diagnosing and monitoring certain brain disorders, such as epilepsy and strokes. However, they are not particularly user-friendly or convenient, with specialized technicians performing time consuming procedures, such as skin preparation, to get patients ready to undergo the procedure. A combination of messy gels and wires also makes ...
By Zeto, Inc.
-
New study tests “first-of-its-kind” EEG device
A press release states that EEG (electroencephalogram) tests are conducted to detect problems in the brain that may be associated with certain brain disorders such as seizures, tumors or strokes. A typical EEG test consists of multiple electrodes attached to a patient’s scalp with adhesive. Those electrodes have several wires connected to an amplifier which further connects to a computer ...
By Zeto, Inc.
-
Methodist University Hospital Is First In The World To Participate In Groundbreaking EEG Study For Inpatients That Improves Brain Monitoring During the COVID-19 Crisis
Methodist Le Bonheur Healthcare (MLH) is the first hospital system globally to participate in a landmark study using a first-of-its-kind EEG device. EEG stands for electroencephalogram. EEG tests are conducted to detect problems in the brain that may be associated with certain brain disorders such as seizures, tumors or strokes. A typical EEG test consists of multiple electrodes attached to a ...
By Zeto, Inc.
-
Kannalife, Inc. Bolsters IP Portfolio with Multiple Patents Issued in 12 Key European Territories
Kannalife, Inc. (“Kannalife” or the “Company”) (OTCQB: KLFE), a biopharmaceutical and medchem company specializing in the research and development of potent novel monotherapeutics, announced today that the Company has been issued patents in Switzerland (CH), Germany (DE), France (FR), United Kingdom (GB), Ireland (IE), Italy (IT), Spain (ES), Belgium (BE), Sweden (SE), ...
-
Kannalife, Inc. Announces Results from Comparative UVB-Radiation Study on Atopidine Versus CBD
DOYLESTOWN, Pa., April 14, 2020 (GLOBE NEWSWIRE) — Kannalife, Inc. (“Kannalife” or the “Company”) (OTCQB: KLFE), a biopharmaceutical medchem company specializing in the research and development of potent novel monotherapeutics, announced today that the studies performed on the Company’s patented compound, Atopidine™, suggest that Atopidine™ has ...
-
Kannalife, Inc. Announces Results from Comparative UVB-Radiation Study on Atopidine Versus CBD
Kannalife, Inc. (“Kannalife” or the “Company”) (OTCQB: KLFE), a biopharmaceutical medchem company specializing in the research and development of potent novel monotherapeutics, announced today that the studies performed on the Company’s patented compound, Atopidine™, suggest that Atopidine™ has outperformed cannabidiol (CBD) in preventing inflammatory ...
-
Kannalife, Inc. Receives Notice of Allowance from USPTO for Trademark of Atopidine
DOYLESTOWN, Pa., April 01, 2020 (GLOBE NEWSWIRE) — Kannalife, Inc. (“Kannalife” or the “Company”) (OTCQB: KLFE), a biopharmaceutical medchem company specializing in the research and development of potent novel monotherapeutics, announced today that the Company has been issued a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for its ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you